Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wu, Guowu
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer	Recruiting	3	450	RoW	camrelizumab + famitinib, pembrolizumab, camrelizumab	Jiangsu HengRui Medicine Co., Ltd.	Non-small Cell Lung Cancer	12/23	12/25
NCT05716087: A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma	Recruiting	2	62	RoW	LP-168, NWP-775	Guangzhou Lupeng Pharmaceutical Company LTD.	Mantle Cell Lymphoma (MCL)	02/24	12/25
NCT05284994: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer	Recruiting	1/2	160	RoW	TQ-B3525 Tablets, Osimertinib Mesylate Tablets	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Nonsmall-cell Lung Cancer	04/24	06/24